Aphotic
Aphoticbio reads the non-coding 98% of the human genome to identify novel, causal disease targets for pharmaceutical development. The company's proprietary computational platform returns targets with their regulatory mechanisms attached, providing human genetic evidence that more than doubles a target's odds of regulatory approval. This approach addresses the root cause of clinical failures—poor target selection—by focusing on the genomic regions traditional pipelines ignore.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Most disease variation sits outside the protein-coding genome, yet human genetic evidence used for drug target selection has been read almost entirely from the 2% of the genome that codes for protein. This narrow focus leads to poor target selection, which is the root cause of roughly 90% of clinical failures — programs fail because the target was never causal in the first place.
Solution
Aphoticbio reads the remaining 98% of the genome to identify novel, causal disease targets with their regulatory mechanisms already attached. The company combines computational biology and proprietary analysis of non-coding genetic variation to return targets that carry strong human genetic support — evidence that more than doubles a target's odds of approval. Rather than optimizing molecular design where the least value is created, Aphoticbio focuses on target selection, providing pharma with novel biology it can believe in. By returning targets with regulatory context included, the company enables drug programs to start with causal biology instead of hopeful guesses.
Target Audience
Pharmaceutical companies and biotech organizations seeking novel, genetically validated drug targets with better odds of clinical success.
Features
- Proprietary analytical platform for interpreting non-coding genetic variation across the full genome
- Target output includes the associated regulatory mechanism, not just the gene identity
- Focus on targets with human genetic support, which more than doubles a target's odds of regulatory approval
- Expertise in the 98% of the genome that traditional genetic evidence pipelines ignore